Search

Kylie Swenson at the beach

Kylie Swenson at the beach

July 10, 2023

Kylie Swenson, 39, is an OHSU clinical trial participant who lives in Central Point. The clinical trial uses a form of chimeric antigen receptor, or CAR-T, to treat generalized myasthenia gravis, or MG, a debilitating autoimmune neurological disease. (Courtesy of Kylie Swenson)

Kylie Swenson, OHSU clinical trial patient

Kylie Swenson, OHSU clinical trial patient

July 10, 2023

Kylie Swenson, 39, is an OHSU clinical trial participant who lives in Central Point. The clinical trial uses a form of chimeric antigen receptor, or CAR-T, to treat generalized myasthenia gravis, or MG, a debilitating autoimmune neurological disease. (Courtesy of Kylie Swenson)

Paul Mitalipov

Paul Mitalipov

July 07, 2023

Paul Mitalipov, 17, recently co-authored a paper with his father Shoukhrat Mitalipov, Ph.D., director of the OHSU Center for Embryonic Cell and Gene Therapy, making the case for using gene-editing tools to prevent inherited disease. (OHSU/Kristyna Wentz-Graff)

Danielle Mitalipov

Danielle Mitalipov

July 07, 2023

Danielle Nargiz Mitalipov, 20, co-authored two papers in 2014 and 2015 while volunteering in her father Shoukhrat Mitalipov's lab. (Photo courtesy of Danielle Mitalipov)

The case for gene editing

The case for gene editing

July 07, 2023

Shoukhrat Mitalipov, Ph.D., (left) director of the OHSU Center for Embryonic Cell and Gene Therapy, co-authored an editorial with his 17-year-old son, Paul Mitalipov, making the case for using gene-editing tools to prevent inherited disease. (OHSU/Kristyna Wentz-Graff)

See More Stories